Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING

Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING

30 Aug 2022 14:25 CEST

The Extraordinary General Meeting in Hofseth BioCare ASA was held at the
premises of the Company in Ålesund, Norway today Tuesday 30 August 2022.

All matters were approved according to the proposals in the notice. Please find
the minutes from the general meeting attached.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: [email protected] (mailto:[email protected])

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung") as
well as in COVID.

Other leads are focused on the protection of the Gastro- Intestinal (GI) system
against inflammation (including ulcerative colitis and the orphan condition
necrotizing enterocolitis) and using peptide fractions of salmon protein
hydrolysate (SPH also known as 'ProGo') as a Medical Food to help treat age-
related Sarcopenia, and as a treatment for Iron Deficiency Anemia. The company
is founded on the core values of sustainability, optimal utilization of natural
resources and full traceability. Through an innovative hydrolysis technology,
HBC can preserve the quality of the lipids, proteins and calcium from fresh
salmon off-cuts.

Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, Ningbo, New Jersey and Palo Alto.

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

More information:
Access the news on Oslo Bors NewsWeb site

570114_Minutes EOGM.pdf

Source

Hofseth BioCare ASA

Provider

Oslo Børs Newspoint